Added to YB: 2025-06-25
Pitch date: 2025-06-22
INMB [bearish]
INmune Bio, Inc.
+67.9%
current return
Author Info
AnthonyStaj shares thoughts and musings on biotech, mostly. L/S, not afraid of indication, highly focused on clinical and commercial analysis. Sign up for the newsletter.
Company Info
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Market Cap
$50.5M
Pitch Price
$5.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.44
P/E
-0.76
EV/Sales
351.78
Sector
Biotechnology
Category
N/A
$INMB: the latest Alzheimer's zero shot
INMB short: Zero chance of success based on 1) Implausible mechanism (Xpro can't cross BBB) 2) Missing/inconsistent PK data (only highest dose reported, no placebo, questionable assays) 3) All prior TNF-pathway trials failed. Biomarker data problematic, no actual efficacy shown. EMACC endpoint lacks validation.
Read full article (18 min)